The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | An ongoing Phase II dose-optimization trial of pirtobrutinib in patients with CLL/SLL
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses the ongoing Phase II dose-optimization trial (NCT06588478) of pirtobrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Prof. Danilov highlights the favorable safety profile of this non-covalent BTK inhibitor, which is being tested at multiple dose levels to determine the optimal dose for maintaining response. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
